Review Article
Cleaning the scope: have randomized clinical trials clarified the benefits of minimally invasive thoracic surgery for non-small cell lung cancer?—a narrative review
AME Clinical Trials Review
2024;
2:
112
(25 December 2024)
Editorial Commentary
Less radiation, same bang, fewer bucks?
AME Clinical Trials Review
2024;
2:
111
(25 December 2024)
Editorial Commentary
Neoadjuvant FOLFIRINOX in resectable pancreatic cancer: impact of the NORPACT-1 trial
AME Clinical Trials Review
2024;
2:
110
(25 December 2024)
Editorial Commentary
Need of the hour—advancements in treatment of pancreatic cancer
AME Clinical Trials Review
2024;
2:
109
(25 December 2024)
Editorial Commentary
Combining [177Lu]Lu-PSMA-617 and enzalutamide in metastatic castration-resistant prostate cancer: promising but with caveats for now
AME Clinical Trials Review
2024;
2:
108
(25 December 2024)
Editorial Commentary
Tislelizumab in hepatocellular carcinoma: a duet or a solo performance?
AME Clinical Trials Review
2024;
2:
107
(25 December 2024)
Editorial Commentary
To fast or not to fast—that is the question?
AME Clinical Trials Review
2024;
2:
106
(25 December 2024)
Editorial Commentary
The COMBAT trial: use of bipolar androgen therapy to enhance immune checkpoint blockade in the management of metastatic castration-resistant prostate cancer
AME Clinical Trials Review
2024;
2:
105
(25 December 2024)
Editorial Commentary
Novel agents in acute lymphoblastic leukemia: an expanding role for inotuzumab ozogamicin in patients with measurable residual disease
AME Clinical Trials Review
2024;
2:
104
(25 December 2024)
Editorial Commentary
Optimizing antiplatelet therapy after coronary artery bypass graft: selection, dosing, and duration
AME Clinical Trials Review
2024;
2:
103
(25 December 2024)
Editorial Commentary
Comparison of drug-eluting bead transcatheter arterial chemoembolization (TACE) versus conventional TACE for hepatocellular carcinoma with portal vein thrombus
AME Clinical Trials Review
2024;
2:
102
(25 December 2024)
Editorial Commentary
FLAURA in the real world: osimertinib in potentially trial-eligible and ineligible patients with EGFR-mutated advanced non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
101
(25 December 2024)
Editorial Commentary
Antiplatelet therapy after coronary artery bypass surgery: the results from the randomized DACAB trial
AME Clinical Trials Review
2024;
2:
100
(25 December 2024)
Editorial Commentary
What is the optimal therapeutic option for patients diagnosed with hormone receptor-positive, HER2-negative breast cancer in visceral crisis?—insights from the RIGHT CHOICE trial
AME Clinical Trials Review
2024;
2:
99
(25 December 2024)
Editorial Commentary
Ficonalkib: a new contender in ALK-positive non-small cell lung cancer treatment
AME Clinical Trials Review
2024;
2:
98
(25 December 2024)
Editorial Commentary
The significance of local intervention for oligometastatic esophageal squamous cell carcinoma
AME Clinical Trials Review
2024;
2:
97
(25 December 2024)
Editorial Commentary
From lifelong therapy to intermittent treatment: the future of chronic myeloid leukemia management—commentary on interim results from DAstop2 trial
AME Clinical Trials Review
2024;
2:
96
(25 December 2024)
Editorial Commentary
Drug-coated ballons finally land in the United States: an appraisal of the agent IDE randomized clinical trial
AME Clinical Trials Review
2024;
2:
95
(25 December 2024)
Editorial Commentary
Review on LAURA: is it a game changer for unresectable stage III EGFR-mutated non-small-cell lung cancer?
AME Clinical Trials Review
2024;
2:
94
(25 December 2024)
Editorial Commentary
Can PET-CT improve the staging and outcome of patients with muscle-invasive bladder cancer?
AME Clinical Trials Review
2024;
2:
93
(25 December 2024)
Editorial Commentary
Can robot-assisted oesophagectomy really improve outcomes?
AME Clinical Trials Review
2024;
2:
92
(25 December 2024)
Letter to the Editor
Are metastatic central lymph nodes (D3 volume) in right-sided colon cancer “REALLY” a sign of systemic disease?—a sub-group analysis of an ongoing multicenter trial
AME Clinical Trials Review
2024;
2:
91
(25 October 2024)
Editorial Commentary
One more point for ibrutinib plus rituximab over fludarabine, cyclophosphamide and rituximab (FCR)
AME Clinical Trials Review
2024;
2:
90
(25 October 2024)
Editorial Commentary
The optimum balance between efficacy and toxicity with different doses of trastuzumab deruxtecan in HER2 mutated non-small cell lung cancer in DESTINY-Lung02 trial
AME Clinical Trials Review
2024;
2:
89
(25 October 2024)
Editorial Commentary
Advancing hepatocellular carcinoma treatment: a triple combination for patients with extrahepatic metastasis—better or bust?
AME Clinical Trials Review
2024;
2:
88
(25 October 2024)
Editorial Commentary
Teamwork makes the dream work?—dissecting the role of triple therapy: radiotherapy combined with sintilimab plus bevacizumab for hepatocellular carcinoma and malignant portal vein invasion
AME Clinical Trials Review
2024;
2:
87
(25 October 2024)
Editorial Commentary
A new ALK inhibitor is not a game changer, but an older one is!
AME Clinical Trials Review
2024;
2:
86
(25 October 2024)
Editorial Commentary
Utilizing therapeutic response as a criterion for PARP inhibitor maintenance therapy in advanced triple negative breast cancer; promoting personalized medicine
AME Clinical Trials Review
2024;
2:
85
(25 October 2024)
Editorial Commentary
Open surgery may no longer be a control arm of minimally invasive surgery for gastric cancer
AME Clinical Trials Review
2024;
2:
84
(25 October 2024)
Editorial Commentary
Tislelizumab: a promising alternative first-line systemic therapy in unresectable advanced hepatocellular carcinoma
AME Clinical Trials Review
2024;
2:
83
(25 October 2024)